Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV

Author(s): Anna Gidari*, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Samuele Sabbatini, Elisabetta Schiaroli, Sara Benedetti, Giulia Gamboni, Alessandra Lanzi and Daniela Francisci

Volume 20, Issue 4, 2022

Published on: 09 September, 2022

Page: [296 - 300] Pages: 5

DOI: 10.2174/1570162X20666220729143949

Price: $65

Abstract

Background: Vaccines have had a fundamental impact in containing the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. However, there are few efficacy data relating to frail patients, including the HIV-positive patient.

Objective: This study evaluated the Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV- 2) serum neutralization in People Living with HIV (PLWH) compared to a cohort of healthy volunteers both vaccinated with BNT162b2.

Methods: A serum sample was then withdrawn 14-21 days after the second dose of the vaccine and a serum neutralization assay was performed on Vero E6 cells. The experiments were performed using two strains of SARS-CoV-2 as 20A.EU1 and B.1.617.2.

Results: PLWH on Antiretroviral Therapy (ART) showed a vaccine response comparable to the healthy subjects. No correlation between CD4 count or CD4/CD8 and neutralizing antibodies (NTAbs) has been found. No differences in NT-Abs between patients with CD4 nadir above or under 200 cells/μl have been found. In both cohorts, vaccine-elicited serum better neutralized 20A.EU1 than B.1.617.2 strain.

Conclusion: PLWH in ART and with good immuno-virological recovery showed a vaccine response comparable to that of healthy subjects and regardless of their immunological status at HIV infection diagnosis. However, larger studies are needed to confirm our results and to evaluate the vaccine response even in patients with low CD4 counts.

Keywords: COVID-19, SARS-CoV-2, vaccine, HIV, PLWH, antibodies, neutralizing.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. General’s opening remarks at the media briefing on COVID-19. General’s opening remarks at the media briefing on COVID-19. 2020.
[2]
Salmerón Ríos S, Mas Romero M, Cortés Zamora EB, et al. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. J Am Geriatr Soc 2021; 69(6): 1441-7.
[http://dx.doi.org/10.1111/jgs.17153] [PMID: 33768521]
[3]
Gidari A, Sabbatini S, Bastianelli S, et al. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. J Infect 2021; 83(4): 467-72.
[http://dx.doi.org/10.1016/j.jinf.2021.07.019] [PMID: 34320390]
[4]
Gidari A, Sabbatini S, Bastianelli S, et al. SARS-CoV-2 Survival on Surfaces and the Effect of UV-C Light. Viruses 2021; 13(3): 408.
[http://dx.doi.org/10.3390/v13030408] [PMID: 33807521]
[5]
Percivalle E, Cambiè G, Cassaniti I, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill 2020; 25(24): 2001031.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.24.2001031] [PMID: 32583766]
[6]
Rahav G, Lustig Y, Lavee J, et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. EClinMed 2021; 41: 101158.
[http://dx.doi.org/10.1016/j.eclinm.2021.101158] [PMID: 34693234]
[7]
Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect 2021; 27(12): 1851-5.
[http://dx.doi.org/10.1016/j.cmi.2021.07.031] [PMID: 34438069]
[8]
Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis 2022; 74(7): 1268-70.
[PMID: 34293114]
[9]
Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf G, et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med 2022; 23(5): 558-63.
[PMID: 34725907]
[10]
Hippisley-Cox J, Coupland CAC, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: National prospective cohort study. BMJ 2021; 374: n2244.
[http://dx.doi.org/10.1136/bmj.n2244] [PMID: 34535466]
[11]
Touizer E, Alrubayyi A, Rees-Spear C, et al. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. Lancet HIV 2021; 8(6): e317-8.
[http://dx.doi.org/10.1016/S2352-3018(21)00099-0] [PMID: 34087093]

Rights & Permissions Print Cite
Article Metrics
7
© 2024 Bentham Science Publishers | Privacy Policy